ライフサイエンスコーパス: excipient

1 tein stability and activity as a formulation excipient.

2 rug micelles containing minimal solubilizing excipient.

3 of trehalose (i.e., as low as 2% w/v) as an excipient.

4 drug that contains polyethylene glycol as an excipient.

5 nsfer reactions and high viscosity of dosing excipients.

6 a whole, i.e., the active ingredient(s) and excipients.

7 in the presence of degradation products and excipients.

8 h a focus on the role of coating formulation excipients.

9 d dosage form, embedded within commonly used excipients.

10 Canada since 1995 that include phthalates as excipients.

11 than those produced by common pharmaceutical excipients.

12 on of APIs relative to common pharmaceutical excipients.

13 induced by protein cofactors and formulation excipients.

14 the sodium salt of the drug and formulation excipients.

15 t significant interferences from formulation excipients.

16 ml excipient twice a day (n = 43) or 2.5 ml excipient alone twice daily (n = 37) along with conventi

17 s containing divalent cations and/or CMCS as excipients, although specific effects were dependent on

18 ion of allergic milk proteins in the lactose excipient and found the smear band by silver staining, w

19 Atf4 (-/-) mice treated with asparaginase or excipient and further explored selected responses in liv

20 d efficiently deliver chemical drugs without excipients and biologics drugs in the presence of sugar

21 fect of pH on resolution, (ii) the effect of excipients and buffering agents, (iii) the performance o

22 d in solution in the presence of stabilizing excipients and frozen after gradual supercooling prior t

23 ers are mainly focused on their functions as excipients and inert carriers of other pharmacologically

24 should use materials safe as pharmaceutical excipients and its formulation (nanomedicine) should hav

25 All high molecular weight auxiliary excipients and mannitol containing formulations were uns

26 w members to the library of functional lipid excipients and open a novel and effective synthetic path

27 r dosage forms in a single-step with minimal excipients and operations.

28 t can encapsulate IPV along with stabilizing excipients and release immunogenic IPV over the course o

29 ation, 6 RX drug products included DBP as an excipient, and 45 specified the use of diethyl phthalate

30 maging of specific ion species for the drug, excipient, and coating materials.

31 ed heparin; compounds tested included drugs, excipients, and larger glycosaminoglycans and their semi

32 Some excipients are foods or substances derived from foods, r

33 Excipients are substances in pharmaceuticals other than

34 Drugs are coated onto balloons using excipients as drug carriers to facilitate adherence and

35 in the number of components assigned in the excipients batch using FTICR-MS, compared to the numbers

36 ition to being a food dye and pharmaceutical excipient, Brilliant Black BN is commonly used within ca

37 Inavir inhaler powder and lactose used as an excipient but negative for Laninamivir.

38 a viscosity enhancer are beneficial coating excipients, but the inclusion of surfactant is detriment

39 A peptide sample and the TFA excipient can be studied simultaneously by FT-IR and 2D

40 maceutical formulations, the interference of excipients can be avoided, a feature cannot achieved by

41 These well-known excipients can be used as admixtures to treat NPC1 disor

42 , or a mixture of sugars and amino acids, as excipients can convert vaccines containing aluminum salt

43 The activation effects of such excipients can reach into the tens and hundreds of fold.

44 -water mutual diffusivity in the presence of excipient cannot generally be taken as a constant.

45 s were dependent on the specific peptide and excipient combinations.

46 The first group of excipients consists of phenolic and aniline substrates a

47 We examine three excipient/contaminant systems, glycerin/diethylene glyco

48 ty are examined as ways to minimize or avoid excipient effects, particularly for very polar compounds

49 to systematically characterize structure and excipient effects.

50 Mannitol is an essential excipient employed in orally disintegrating tablets due

51 y was relatively low (<8%) in the absence of excipient emulsions due to the crystalline nature of the

52 Overall, this study shows that excipient emulsions may increase the bioaccessibility of

53 The use of excipient emulsions to increase the bioaccessibility of

54 systems usually substitute one solubilizing excipient for another, bringing new issues to consider.

55 of reducing sugars in the formulation of an excipient for the stabilization of dried protein is not

56 Recent developments in cyclodextrins as excipients for anesthetics may soon culminate in their i

57 o the arterial wall include finding suitable excipients for drug formulation to enable drug release t

58 o design improved low-calorie sweeteners and excipients for food and pharmaceutical preparations.

59 se degradable polymers were then employed as excipients for the stabilization of the therapeutic prot

60 Alternatives like 'top-down' fine milling of excipient-free injectable drug suspensions are not yet c

61 0 succinate (TPGS) is an important polymeric excipient frequently used in drug formulation.

62 possible to differentiate between batches of excipients from differences in the identified components

63 Therefore, a comparison between excipients from different suppliers and batches to batch

64 oreover, the activations afforded by the two excipient groups are additive, resulting in up to a comp

65 of the active pharmaceutical ingredients and excipients held in the product.

66 complex structures and compositions of drug excipients impact performance of the formulation in vivo

67 ved as a generally recognized as safe (GRAS) excipient in 1985 by the United States Food and Drug Adm

68 The lactose excipient in Inavir inhaler powder was supposed to conta

69 an be used to ascertain the presence of this excipient in peptide samples for quality assessment.

70 ECH-CL-CMRSs could potentially be used as an excipient in pharmaceutical and food/food supplement pro

71 pound, the concentration-time profile of the excipient in plasma from rats dosed both orally and intr

72 e and the interference from proteins and the excipient in the formulation matrix make it a challenge

73 arameters for coated MNs include the role of excipients in assisting dissolution from the MNs, the in

74 mAb but not associated with the formulation excipients in both light-irradiated and heat-stressed mA

75 use of Gelucire 44/14 and polysorbate 80 as excipients in drugs, they are also widely used as cosmet

76 therapeutic categories may use DBP or DEP as excipients in oral dosage forms.

77 Cyclodextrins are well-known excipients in the pharmaceutical industry.

78 tations and high levels of interference from excipients in typical biologic formulations have prevent

79 erived substances are used as pharmaceutical excipients in which medications and reviews published da

80 medicinal products containing phthalates as excipients (inactive ingredients).

81 ious factors such as mutations, buffers, and excipients influencing protein aggregation propensity un

82 troscopy (ATR-FTIR) were used to assess drug-excipient interaction.

83 API-excipient interactions were observed in high-sensitivity

84 calculated plasma clearance values when the excipient interferes with the quantitation of the dosed

85 n of topically applied drugs and formulation excipients into porcine skin.

86 and biologics drugs in the presence of sugar excipients into the skin with a duration of 12h.

87 iate co-formulation of vaccine antigens with excipients known to influence mucosal barrier functions

88 ounts of beta-LG contaminated in the lactose excipient of Inavir could cause immediate allergic react

89 f both active pharmaceutical ingredients and excipients of a drug tablet.

90 rkflow to study the effect of several common excipients on insulin folding stability.

91 p53 and Flt3L than in mice receiving Flt3L, excipient, or p53 treatment alone.

92 Because of the differences in excipients, paclitaxel dose, and coating morphologies, v

93 to enhanced tabletability without the use of excipients, particle coating, salt, or cocrystal formati

94 These excipient plasma concentrations can result in a 2-5-fold

95 ure, pH, salts, detergents, denaturants, and excipients), post-translational modifications, self-asso

96 The drug:excipient ratio is restricted to 10:1 w/w to maximise do

97 ained release profiles based upon the active/excipient ratio used.

98 The mechanism of excipient-related signal interference is discussed in re

99 perspective but formulation with additional excipients requires careful evaluation for drug delivery

100 responses (present as low as 0.14% w/w) over excipient responses such as poly(ethylene glycol).

101 utility, we applied the correction to HX-MS excipient screening data collected for a pharmaceuticall

102 We show that it is possible to reduce excipient signals and allow focus on structural characte

103 roduced signals >10(4)-fold greater than the excipients studied.

104 The addition of excipients such as mannitol is optimized for both the st

105 The effect of dosing vehicle excipients such as PEG400, propylene glycol, Tween 80, a

106 Common organic excipients such as sucrose, lactose, stearate, dextrin,

107 ive ion mode MS or changing a dosing vehicle excipient, such as substituting propylene glycol for PEG

108 urce CID of ions derived from pharmaceutical excipients, sufficiently close in m/z (17.7 ppm mass dif

109 lly examine the effect of key bulking agents/excipients - sugars/polyols - on the material form, stru

110 e and dextran (and various low concentration excipients targeting different mechanisms of damage), an

111 ing its propensity to associate with various excipients that can optimize its transfer and retention.

112 ing insulin analogues, creating a demand for excipients that limit aggregation.

113 protein aggregation and the rational use of excipients to inhibit the process.

114 ulation was performed with several auxiliary excipients to obtain nano-sized amorphous powder formula

115 olymer or a lipid component along with other excipients to stabilize the colloidal system.

116 h involving the addition of certain types of excipients to the aqueous enzyme solution before lyophil

117 ndomized to receive rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43) or 2.5 ml excipient alone

118 Two polymeric excipients, typically used in enabling drug delivery app

119 Thus, ostensibly unreactive excipients under certain conditions may increase heterog

120 ) is a Food and Drug Administration-approved excipient used to improve the stability and bioavailabil

121 solution without any molecular precursor or excipient via collaborative interactions (electrostatic,

122 y important when dealing with pharmaceutical excipients, which are susceptible to economically motiva

123 improved through the addition of saccharide excipients without detriment to the biological functiona